Research programme: biodefence antibodies - Nanotherapeutics

Drug Profile

Research programme: biodefence antibodies - Nanotherapeutics

Alternative Names: Anti-H1N1 (swine flu) antibodies - XOMA; Anti-H5N1 (bird flu) antibodies - XOMA; Anti-influenza A antibodies - XOMA; Anti-severe acute respiratory syndrome (SARS) antibodies - XOMA; Antibotulinum toxin antibodies - XOMA; Antibotulism antibodies - XOMA; Biodefense antibodies - XOMA; F10 antibody - XOMA; XOMA 3EB

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard Medical School; University of California at San Francisco
  • Developer XOMA
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Botulism; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype
  • Research Severe acute respiratory syndrome

Most Recent Events

  • 05 Nov 2015 Nanotherapeutics acquires biodefence antibodies programme from XOMA
  • 07 Oct 2011 Preclinical development is ongoing for Botulism, Influenza A virus and Severe acute respiratory syndrome in the US.
  • 03 Oct 2011 Xoma receives grant from NIAID for continued development of antibotulism antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top